Header
Sir Ganga Ram Hospital, New Delhi
Lung Cancer Stages, Survival Rates and Treatment.
Medically Reviewed by Dr. Aditya Sarin, MD, DrNB
Cancer Care · Sir Ganga Ram Hospital, New Delhi

Understanding Lung Cancer
Your Complete Guide.

A comprehensive overview of lung cancer — what it is, its types, causes, and treatment options — explained clearly by Dr. Aditya Sarin, so you can approach diagnosis and care with confidence.

Medical Disclaimer

This page is for informational purposes only and does not constitute medical advice, diagnosis or treatment. Every case of lung cancer is different. Please consult Dr. Aditya Sarin or a qualified oncologist for evaluation, diagnosis and a treatment plan specific to your condition.

85%
of cases are
Non-Small Cell
Lung Cancer
Simple Overview
The Lung Cancer Journey at a Glance
1

Early Detection

Recognising symptoms early and seeking timely screening improves outcomes significantly.

2

Accurate Diagnosis

Scans, biopsies, and molecular testing confirm the cancer type and stage precisely.

3

Personalised Treatment

Surgery, chemotherapy, targeted therapy, or immunotherapy — tailored to your case.

4

Ongoing Support

Follow-up care, rehabilitation, and emotional support throughout your recovery journey.

Section 01

What is Lung Cancer?

Lung cancer is a type of cancer that starts in the lungs when abnormal cells grow uncontrollably. It is one of the most common and serious types of cancer worldwide, often associated with smoking but also occurring in non-smokers due to genetic, environmental, and other factors.

Lung cancer may not cause noticeable symptoms in its early stages, making regular screening crucial — especially for those at higher risk. Early detection dramatically improves the likelihood of successful treatment.

Starts in the Lungs

Abnormal cells in lung tissue divide uncontrollably, forming a tumour that can grow and spread.

Can Spread to Other Organs

Without treatment, lung cancer can metastasize to the brain, bones, liver, and adrenal glands.

Highly Treatable if Caught Early

Stage I and II lung cancers have significantly better outcomes with surgical and targeted treatments.

Multiple Treatment Options

Modern oncology offers surgery, chemotherapy, targeted therapy, immunotherapy, and radiation — often in combination.

Section 02

Types of Lung Cancer

Lung cancer is primarily classified into two major categories based on how the cancer cells look under a microscope. Each type behaves differently and requires a distinct treatment approach.

NSCLC · 85% of cases

Adenocarcinoma

The most common subtype, often found in non-smokers. Usually starts in the outer regions of the lungs and is associated with specific gene mutations targetable with precision therapy.

NSCLC · Smokers

Squamous Cell Carcinoma

Strongly linked to smoking, this type is found in the central airways of the lungs and is often detected when it causes breathing obstruction or bleeding.

NSCLC · Rare

Large Cell Carcinoma

A rare and aggressive form of non-small cell lung cancer that can appear anywhere in the lungs and tends to grow and spread quickly.

SCLC · 15% of cases

Small Cell Lung Cancer

A fast-growing cancer almost exclusively found in heavy smokers. It spreads rapidly to other organs and is typically treated with chemotherapy and radiation rather than surgery.

Section 03

Symptoms of Lung Cancer

Lung cancer may not cause noticeable symptoms in its early stages. As the disease progresses, the following signs may appear. Persistent or unexplained symptoms should prompt immediate medical evaluation.

Persistent cough that worsens over time
Coughing up blood (haemoptysis)
Shortness of breath or wheezing
Chest pain or persistent discomfort
Unexplained weight loss
Loss of appetite
Frequent respiratory infections (pneumonia, bronchitis)
Hoarseness or voice changes

Early detection saves lives. If you experience a persistent cough, chest pain, or breathing difficulties, do not delay — book an appointment with Dr. Aditya Sarin today for a thorough evaluation.

Section 04

Causes & Risk Factors

Several factors can increase the risk of developing lung cancer. While smoking remains the leading cause, lung cancer also affects non-smokers due to environmental and genetic factors.

Smoking The leading cause, responsible for approximately 85% of all lung cancer cases. Both duration and intensity of smoking increase risk significantly.
Secondhand Smoke Exposure Prolonged exposure to cigarette smoke from others raises lung cancer risk in non-smokers as well.
Air Pollution & Environmental Toxins Long-term exposure to air pollution, asbestos, radon gas, or industrial chemicals such as arsenic and chromium.
Family History & Genetics A genetic predisposition to lung cancer can increase risk, even in those who have never smoked.
Radiation Exposure & Chronic Lung Disease Previous chest radiation therapy, or chronic conditions such as COPD and pulmonary fibrosis, can elevate risk.
Section 05

Diagnosis of Lung Cancer

Early and accurate diagnosis is critical to achieving the best treatment outcomes. Dr. Aditya Sarin uses the latest diagnostic tools to confirm the presence, type, and stage of lung cancer with precision.

Chest X-ray

The initial screening tool used to detect visible lung abnormalities, masses, or shadows that warrant further investigation.

CT Scan

Provides detailed cross-sectional imaging of the lungs to identify the size, location, and extent of any tumours and lymph node involvement.

Biopsy

A tissue sample is collected via bronchoscopy, CT-guided needle biopsy, or surgery to definitively confirm cancer and determine its exact type.

PET Scan

Detects metabolically active cancer cells throughout the body, revealing whether cancer has spread to other organs or lymph nodes.

Molecular & Genetic Testing

Identifies specific gene mutations (EGFR, ALK, ROS1, KRAS) that guide the selection of targeted therapies for personalised treatment.

Section 06

Stages of Lung Cancer

Staging describes how far the cancer has spread and directly shapes the treatment approach. Non-small cell lung cancer, which accounts for 85 percent of cases, is staged using the AJCC TNM system into Stages I through IV. Small cell lung cancer, the remaining 15 percent, uses a simpler limited or extensive staging system instead, reflecting how differently the two types behave. This staging guidance is current as of 2026.

Stage
What it means
Stage I
A small tumour confined to the lung, with no spread to lymph nodes.
Stage II
A larger tumour, or spread to nearby lymph nodes within the lung.
Stage III
Locally advanced cancer that has spread to lymph nodes in the centre of the chest, but not to distant organs.
Stage IV
Metastatic cancer that has spread to the other lung, fluid around the lungs, or distant organs such as the brain, bones, or liver.
Small cell lung cancer is instead described as limited stage — confined to one lung and nearby lymph nodes — or extensive stage — spread beyond that to the other lung or distant organs.

Source: American Cancer Society, Non-small Cell Lung Cancer Stages.

Section 07

Survival Rates by Stage

Survival statistics are population averages. They describe outcomes across large groups of patients and do not predict what will happen to any individual patient.

Lung cancer survival rate in the US — Non-small cell lung cancer

Stage at diagnosis
5-year rate
Localized — confined to the lung
67%
Regional — spread to nearby structures or lymph nodes
40%
Distant — spread to other organs
12%
All stages combined
32%

Source: American Cancer Society, Lung Cancer Survival Rates, based on SEER data for cases diagnosed between 2015 and 2021.

Lung cancer survival rate in the US — Small cell lung cancer

Stage at diagnosis
5-year rate
Localized — confined to the lung
34%
Regional — spread to nearby structures or lymph nodes
20%
Distant — spread to other organs
4%
All stages combined
9%

Source: American Cancer Society, Lung Cancer Survival Rates, based on SEER data for cases diagnosed between 2012 and 2018.

Lung cancer survival rate in India

Nationally representative, stage-wise survival data specific to lung cancer is limited in India. Published research citing National Cancer Registry Programme data notes that developing countries, including India, report a mean 5-year survival of around 15 percent — roughly three times lower than developed countries — largely because 75 percent of cases in India are diagnosed at Stage III or IV.

Source: Indian Journal of Medical Research, A clinicoepidemiological profile of lung cancers in India, results from the National Cancer Registry Programme, 2022.

Section 08

Treatment Options for Lung Cancer

The treatment approach is tailored to the cancer type, stage, and the patient's overall health. Dr. Aditya Sarin offers a comprehensive, multidisciplinary approach covering all established and emerging treatment modalities.

Surgery

Lobectomy, pneumonectomy, or segmentectomy — the appropriate procedure depends on tumour size, location, and stage. Offers the best chance of cure in early-stage disease.

Radiation Therapy

High-energy beams target and destroy cancer cells while minimising damage to surrounding healthy tissue. Often combined with chemotherapy.

Chemotherapy

Drug treatment used to kill cancer cells, often given before surgery (neoadjuvant), after surgery (adjuvant), or as the primary treatment in advanced cases.

Targeted Therapy

Precision medicines that target specific genetic mutations (EGFR, ALK, ROS1) in cancer cells to block their growth with fewer side effects than chemotherapy.

Immunotherapy

Checkpoint inhibitors such as PD-1/PD-L1 blockers help the immune system recognise and fight lung cancer cells more effectively, especially in advanced NSCLC.

Palliative Care

For advanced cancer, palliative care focuses on relieving symptoms, improving quality of life, and providing holistic support to patients and their families.

Section 09

Latest Advances in Lung Cancer Treatment

Lung cancer treatment has advanced significantly over the past year, particularly in precision therapies matched to specific genetic mutations. As of 2026, notable developments include the following.

1
FDA Precision Oncology · 2025

A strong year for precision oncology in NSCLC

The FDA approved seven new biomarker-driven therapies for non-small cell lung cancer in 2025 alone, covering mutations including EGFR, HER2, MET, and ROS1.

Among them, datopotamab deruxtecan received accelerated approval in June 2025 for EGFR-mutated NSCLC that has progressed after standard treatment.

Source: Biomolecules and Biomedicine — A remarkable year for NSCLC, seven new FDA approvals in 2025 across molecular targets, 2026.

2
FDA Approval · February 26, 2026

Expanded option for HER2-mutant NSCLC

On February 26, 2026, the FDA approved zongertinib for adults with advanced NSCLC whose tumours carry HER2 tyrosine kinase domain activating mutations — expanding on its original accelerated approval from August 2025.

Source: Boehringer Ingelheim — FDA Approves Targeted Therapy for HER2-Mutant Advanced NSCLC, 2026.

3
ALINA Trial · ALK-positive NSCLC

First adjuvant targeted therapy for ALK-positive NSCLC

Based on the ALINA trial, adjuvant alectinib was approved for resected, early-stage ALK-positive NSCLC — reducing the risk of recurrence or death by 76 percent compared with chemotherapy.

This is the first molecularly targeted adjuvant therapy specifically for this subtype.

Source: Non-small cell lung cancer in 2026, a narrative review of clinical advances and systemic challenges, ScienceDirect.

Whether any of these apply to a given patient depends on molecular and genetic testing results, cancer type, and stage, and should be discussed directly with an oncologist.
Section 10

Life After Lung Cancer Treatment

Completing treatment is a significant milestone. Recovery focuses on rebuilding lung function, physical strength, and emotional wellbeing — with comprehensive support at every step.

Regular Follow-ups

Scheduled scans and check-ups to monitor for recurrence, manage long-term side effects, and assess overall health.

Lifestyle Changes

Guidance on quitting smoking, maintaining a healthy diet, and staying physically active to support long-term recovery and reduce recurrence risk.

Pulmonary Rehabilitation

Structured breathing exercises, physiotherapy, and pulmonary programmes to restore lung function and improve exercise capacity.

Emotional & Psychological Support

Counselling, peer support groups, and mental health resources for patients and their families throughout and after treatment.

Section 11

Facing Lung Cancer with Confidence

"Early detection, precise diagnosis, and a personalised treatment plan are the cornerstones of the best possible outcome in lung cancer care."

— Dr. Aditya Sarin, Medical Oncologist
Advanced molecular testing allows treatment to be matched precisely to your cancer's genetic profile.
Targeted therapies and immunotherapy offer effective options with fewer side effects than traditional chemotherapy.
Early-stage lung cancer is highly treatable — survival rates have improved significantly with modern care.
A multidisciplinary team ensures every aspect of your treatment and recovery is coordinated and supported.
Understanding your diagnosis and treatment options gives you agency and confidence throughout the journey.
Section 12

Frequently Asked Questions about Lung Cancer

Can non-smokers get lung cancer?

Yes. While smoking causes approximately 85 percent of lung cancer cases, non-smokers can still develop the disease due to genetic factors, radon exposure, secondhand smoke, or air pollution. Adenocarcinoma, the most common lung cancer subtype, is frequently seen in non-smokers.

What is the difference between non-small cell and small cell lung cancer?

Non-small cell lung cancer accounts for about 85 percent of cases and tends to grow more slowly, while small cell lung cancer, about 15 percent of cases, grows and spreads faster and is treated differently, typically with chemotherapy and radiation rather than surgery.

Is lung cancer screening recommended for everyone?

No. Low-dose CT screening is generally recommended only for people at high risk, such as long-term heavy smokers within a specific age range, rather than the general population, since screening carries its own risks for people at average risk.

What does molecular or genetic testing add to lung cancer treatment?

It identifies specific mutations such as EGFR, ALK, ROS1, or KRAS that can be targeted with precision drugs, often with better results and fewer side effects than standard chemotherapy. This testing has become a standard step in planning treatment for non-small cell lung cancer.

Can lung cancer spread without causing symptoms?

Yes, particularly in its early stages. Lung cancer often produces no noticeable symptoms until it has grown or spread, which is why regular screening is important for people at high risk rather than waiting for symptoms to appear.

Is immunotherapy an option for all lung cancer patients?

Not for all patients. Immunotherapy, particularly checkpoint inhibitors, tends to work best in specific situations, such as tumours with high PD-L1 expression, and is generally used for non-small cell lung cancer rather than small cell lung cancer, based on individual testing results.

What is the best treatment approach for Lung Cancer in Delhi?

Effective lung cancer treatment in Delhi increasingly depends on molecular and genetic testing to identify mutations such as EGFR and ALK, since this determines whether targeted therapy is a better option than standard chemotherapy. Dr. Aditya Sarin offers this molecular testing and targeted treatment pathway for lung cancer patients at Sir Ganga Ram Hospital, New Delhi.
Section 13 · Why Dr. Aditya Sarin

Why Trust Dr. Aditya Sarin for Lung Cancer Care?

ESMO Board Certified · Harvard Trained · Sir Ganga Ram Hospital, New Delhi

Expert Oncology Care

ESMO Board Certified oncologist with advanced training in precision oncology and cancer genomics from Harvard Medical School, specialising in lung cancer diagnosis and treatment.

Advanced Technology

Cutting-edge diagnostic tools including PET-CT, EBUS bronchoscopy, and next-generation molecular sequencing for accurate staging and treatment selection.

Multidisciplinary Care

Integrated team approach combining surgery, chemotherapy, targeted therapy, radiation, and palliative care for holistic patient management.

Post-Treatment Support

Comprehensive rehabilitation, lifestyle guidance, pulmonary therapy, and mental health support to help you thrive after treatment.

Mon – Fri (Morning) 10:00 AM – 12:00 PM
Mon – Fri (Evening) 4:00 PM – 6:00 PM
Saturday - Sunday Closed

Book Your Lung Cancer Consultation

"Early detection saves lives — don't wait for symptoms to progress."

Speak with Dr. Aditya Sarin to discuss your symptoms, understand your diagnosis, and take the first step toward the best possible outcome.

📅 Book Your Consultation

Lung Cancer